Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00078325 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00078325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00078325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome
Lead sponsor
Cephalon
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2004
Completion date
November 30, 2004
Enrollment
395 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypopnea, obstructive sleep apnea